TonsillitisPhase 4NCT03323047
Perioperative Tonsillectomy Protocol Development
A Phase 4 study testing Acetaminophen, Low-dose Dexamethasone and High-Dose Dexamethasone in people with Tonsillitis, run by London Health Sciences Centre at 1 site in Canada.
Trial summary
Pediatric patients who are undergoing a tonsillectomy at the Children's hospital will be randomly assigned to one of three drug groups: 1) acetaminophen (Tylenol) administered pre-operatively and a low dose of anti-inflammatory drug (dexamethasone) administered intra-operatively; 2) acetaminophen (Tylenol)… Read more about this study
- Who is it for?
- Ages 3 to 13 years
- Conditions the study is for
- Tonsillitis
- What is being tested?
- Acetaminophen, Low-dose Dexamethasone and High-Dose Dexamethasone
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteCanada
- Study dates
- 1 Mar 2018to Sep 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 13 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Healthy patients
- aged 3-13 years
- Level I or level II on the American Society of Anesthesiologists (ASA) physical status classification system (as determined by the anesthesiologist)
- obstructive sleep apnea or recurrent throat infections
- undergoing elective tonsillectomy with or without adenoidectomy
- Parents who agree to complete documentation and follow up at 14 days post-operation.
Who cannot join
- Patients Level III or greater on the American Society of Anesthesiologists (ASA) physical status classification system (as determined by the anesthesiologist)
- Patients with chronic conditions that would limit our ability to develop the study according to objectives, such as neurodevelopmental conditions preventing patients from understanding the Oucher tool
- Hepatic or renal disease
- cardiac disease
- active infection
- diabetes mellitus
Show all 15Show fewer
- sickle cell disease
- known coagulation disorders
- pre- operative treatment with anti-emetics, steroids, or analgesics
- Acetaminophen allergy or already receiving acetaminophen within 24 h of surgery
- Complicating health factors precluding the use of opioids or acetaminophen
- any other factors which would interfere with pain assessment and management
- Patients weighing more than 30 kg that would exceed maximum dexamethasone dose
- Patients who live without a home telephone
- patient living without parental supervision.
Trial locations and contacts
1 site in 1 country.
Canada1 site, 1 recruiting
- Recruiting
Children's Hospital
London, Ontario
Alexandria Houston, 519-685-8500 ext. 57125, Alexandria.Houston@lhsc.on.ca
Josee Paradis, MD
About this study
Official title: Perioperative Tonsillectomy Protocol Development for Preoperative Acetaminophen and Intraoperative High Dose Dexamethasone: a Randomized Control Trial
Pediatric patients who are undergoing a tonsillectomy at the Children's hospital will be randomly assigned to one of three drug groups: 1) acetaminophen (Tylenol) administered pre-operatively and a low dose of anti-inflammatory drug (dexamethasone) administered intra-operatively; 2) acetaminophen (Tylenol) administered pre-operatively and a high dose of anti-inflammatory drug (dexamethasone) administered intra-operatively; 3) no acetaminophen (Tylenol) administered pre-operatively, low dose anti-inflammatory (dexamethasone) administered intra-operatively. The present study will evaluate differences in pain management and surgical complications across the three groups of drug regimens. Main study outcomes include: pain medication administration during surgery, use of pain killers at 1-week post-operation, subjective pain scores administered in the post-anesthesia care unit (PACU) and 1 week postoperation, fluid and food intake, and complication rates (i.e. postoperative bleed rate). The hypothesis is that pain will be lowest in the group that received Tylenol and high-dose dexamethasone (Group 2).
Read the detailed description
This study will be conducted as a prospective, randomized, longitudinal, double-blinded trial at a single ambulatory surgery centre with 3 groups of 20 children. Group 1 will receive oral acetaminophen (15 mg/kg) 1 hour pre-operatively and high-dose intravenous dexamethasone (0.5 mg/kg, max. dose 10 mg) immediately after induction of anesthesia. Group 2 will receive oral acetaminophen elixir (15 mg/kg) 1 hour pre-operatively and low-dose intravenous dexamethasone (0.15 mg/kg, maximum of 8 mg) immediately after induction of anesthesia. Group 3 will receive an oral placebo 1 hour pre-operatively and low dose intravenous dexamethasone (0.15 mg/kg, maximum of 8 mg) immediately after induction of anesthesia. Dose of dexamethasone is a potential confounder if patients in the low-dose dexamethasone groups weigh enough to obtain the maximum dose (8 mg). We expect this occurrence to be rare, as dexamethasone will be dosed for ideal bodyweight, but subgroup analysis by actual dose received will be performed to compare the two dosing regimens (0.15mg/kg and 0.5 mg/kg).
In addition to these medications, patients will receive the standard peri-operative care at our centre, which consists of intra- operative ondansetron at the discretion of the anesthesiologist, and standing orders for acetaminophen (15 mg/kg) and ibuprofen (10 mg/kg) around the clock. Patients older than five years also receive morphine elixir (0.1 mg/kg rounded down to the nearest 0.5 mg) p.r.n (when necessary) at the discretion of the nurse. Thus, patients of all three groups will receive adequate post-operative symptom control. The Pediatric Otolaryngologist (Dr. Josee Paradis, Dr. Julie Strychowsky, or Dr. Murad Husein) who is the patient's physician and will be performing the tonsillectomy, will initially approach the participant and substitute decision maker (SDM) to describe the study. If the patient and SDM agree to consider the study, the study will be described in more detail and study consent/assent will be obtained by a research assistant or a physician (who is not the primary physician). We will recruit a convenience sample of 60 patients aged 3-13 years scheduled for tonsillectomy to be performed by the principal investigator or co-investigators (J.P., M.H. or J.S.). For children aged 3 to 6 years, SDM informed consent will be obtained; for children aged 7 to 12 years, SDM written consent and child assent will be requested; for children 13 years of age, written consent will be obtained from a SDM and from the child. The patients will be randomized to one of the three treatment groups by a computerized randomization table. Data from the tonsillectomy procedure, including whether analgesia was needed intraoperatively, and in the post-anesthesia care unit, will be recorded. Self-reported pain intensity will be scored on the Oucher tool, a number and picture scale validated in children age 3-13. A research assistant or nurse will be trained to obtain Oucher reports at the patient's bedside at specific post-operative events, which correspond to time points. The Oucher tool is simple to learn and takes minimal time to administer. The first pain report will be obtained once the patient wakes from anesthesia (15 - 45 min post- operation), then upon transfer to step-down care (1 - 2 hrs hour post-operation), then at 3 hours post-operation, and finally upon discharge (or at 5 hours post-operation, if the patient is not anticipated to be discharged by this time). Many of the details surrounding the operation will be gathered in post-hoc review of the patient's chart by the research assistant. If the patient is transferred from the PACU to the day surgery unit (i.e. discharge is anticipated before the end of the day), the information from the entire stay in the day surgery will be collected. If the patient is admitted to the floor (i.e. staying overnight in the hospital for observation), information will be collected from the first 4 hours after admission. The information gathered from the chart will include complications of surgery, whether or not the patient had post-operative bleeding requiring a change in management, and also whether or not the patient had post-operative bleeding that required an operating room procedure. Time to first oral fluid intake, as well as amount of oral intake (measured in quantity of popsicles) in the post-anesthesia care unit and total oral intake before discharge will also be gathered from the patient's chart, as well as the time to first administration of morphine, the dose of morphine required, and the frequency of post-operative vomiting until time of discharge. For home pain management, all patients are advised to take acetominophen (15mg/kg) every 6 hours as needed, alternating with ibuprofen (10mg/kg) every 6 hours as needed. At discharge (average 5 hours post-operation), parents/guardians will be provided with a package including the Pediatric Quality of Life Inventory with questions about oral intake and activity, as well as a space to record any incidents of vomiting, the Oucher tool to evaluate the patient's pain severity, and a medication log to keep track of the pain medication (over the counter or prescribed) that the patient has taken. Parents/guardians will be given a measured cup to record quantity of oral fluid intake for the day. Parents will be asked to fill out the first questionnaire at discharge (average 5 hours post-operation) time point, and they will be encouraged to raise any questions or concerns they have about how to complete the questionnaires. Subsequently, these instruments will be completed by parents/guardians (relationship to patient will be noted on each form and they will be encouraged to have the same parent/guardian complete the form each time) on post-operative days 1, 2, 3, 4, 5, 6, and 7 before bedtime. The research assistant will contact parents/guardians and patients by telephone on the first postoperative day to follow-up with any questions or concerns about the survey. On the last weekday before the patient's follow-up appointment, a reminder call will be made to ask the parent/guardian to bring their completed questionnaire to the appointment. On the 14th post-operative day patients will attend a follow-up visit where they will be assessed and their completed forms will be collected. If the patient had any emergency department visits related to the procedure, the research assistant will consult the hospital database to obtain information about the emergency department visit, including date, chief complaint, and management.
- Conditions
- Tonsillitis
- Being tested
- Acetaminophen, Low-dose Dexamethasone, Placebo Oral Tablet, High-Dose Dexamethasone
- Keywords
- tonsillectomy, acetaminophen, dexamethasone
- Medical subject headings
- Tonsillitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AcetaminophenDrug
Also called Tylenol
Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
Low-dose DexamethasoneDrug
Also called Dexamethasone sodium phosphate
Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
Placebo Oral TabletDrug
Also called Placebo
Oral placebo 1 hr pre-operatively
High-Dose DexamethasoneDrug
Also called Dexamethasone sodium phosphate
Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Experimental | Acetaminophen and High-dose dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia. Receives: Drug: Acetaminophen; Drug: High-Dose Dexamethasone |
| Group 2 | Active comparator | Acetaminophen and Low-dose Dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia Receives: Drug: Acetaminophen; Drug: Low-dose Dexamethasone |
| Group 3 | Placebo comparator | Placebo oral tablet and Low-dose Dexamethasone: an oral placebo given 1 hr pre-operatively and intravenous administration of low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia. Receives: Drug: Low-dose Dexamethasone; Drug: Placebo Oral Tablet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Oucher pain score
pain intensity on the Oucher pain tool, which includes ratings by face scale and a number scale (0-10).
Measured: awakening from anesthesia (0.5 hours post- operation)
Secondary outcomes (8)
Analgesia use
Whether or not intraoperative analgesia was required
Measured: during operation
time to first oral fluid intake
amount of time that elapses before patient has a fluid intake
Measured: during patient's stay in PACU (on average 5 hours)
time to first request for morphine
the time that elapses before patient requests morphine (if applicable)
Measured: during patient's stay in PACU (on average 5 hours)
dose of morphine required
if morphine administered, frequency, dosage and total amount of morphine patient took post-operatively
Measured: from end of operation to 7 days post-operation
vomiting
Number of times patient vomited after surgery
Measured: From end of operation to 7 days post-operation
Pediatric Quality of Life Inventory
Validated post-tonsillectomy Quality of life questionnaire with Likert-scale questions regarding common post-operative symptoms
Measured: Upon discharge (on average 5 hours post-operation), and 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days post-operation
Medication log
Record of pain medications (over the counter and prescription) patient as taken post-discharge from hospital
Measured: discharge (on average 5 hours post-operation) to 7 days post-operation
Oucher pain score
pain intensity on the Oucher pain tool, which includes ratings by face scale and a number scale (0-10).
Measured: transfer to step-down care (1 hour post-operation), 3 hours post-operation, 5 hours post-operation, upon discharge, as well as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days post-operation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2017
- Study start1 Mar 2018
- Primary completionMay 2021 (estimated)
- Study completionSep 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TonsillitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A prospective, randomized, longitudinal, double-blinded trial at a single centre with 3 groups of 20 children each. Group 1 receives acetaminophen (15 mg/kg) 30 min-1 hr pre-operatively and high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia. Group 2 receives acetaminophen (15 mg/kg) 30 min- 1 hr pre-operatively and low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia. Group 3 receives placebo 1 hr pre-operatively and low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia. We will recruit a convenience sample of 60 patients aged 3-13 scheduled for tonsillectomy with the principal investigator or co-investigators. The patients will be placed in one of the groups by a computerized randomization table.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- London Health Sciences Centre
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Josee Paradis, London Health Sciences Centre
- Investigators
- Josee Paradis, MD, Principal investigator, LHSC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03323047
- Sponsor's protocol ID
- 109757
- Status last verified
- Feb 2021
- First submitted
- 13 Oct 2017
- Last updated
- 18 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perioperative Tonsillectomy Protocol Development for Preoperative Acetaminophen and Intraoperative High Dose Dexamethasone: a Randomized Control Trial
- ClinicalTrials.gov ID
- NCT03323047
- Acronym / sponsor ID
- 109757
- Conditions
- Tonsillitis
- Keywords
- tonsillectomy, acetaminophen, dexamethasone
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- London Health Sciences CentreUniversity, hospital or other
- Study start
- 1 Mar 2018 (actual)
- Primary completion
- May 2021 (estimated)
- Study completion
- Sep 2021 (estimated)
- First posted
- 26 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pediatric patients who are undergoing a tonsillectomy at the Children's hospital will be randomly assigned to one of three drug groups: 1) acetaminophen (Tylenol) administered pre-operatively and a low dose of anti-inflammatory drug (dexamethasone) administered intra-operatively; 2) acetaminophen (Tylenol) administered pre-operatively and a high dose of anti-inflammatory drug (dexamethasone) administered intra-operatively; 3) no acetaminophen (Tylenol) administered pre-operatively, low dose anti-inflammatory (dexamethasone) administered intra-operatively. The present study will evaluate differences in pain management and surgical complications across the three groups of drug regimens. Main study outcomes include: pain medication administration during surgery, use of pain killers at 1-week post-operation, subjective pain scores administered in the post-anesthesia care unit (PACU) and 1 week postoperation, fluid and food intake, and complication rates (i.e. postoperative bleed rate). The hypothesis is that pain will be lowest in the group that received Tylenol and high-dose dexamethasone (Group 2).
Detailed description
This study will be conducted as a prospective, randomized, longitudinal, double-blinded trial at a single ambulatory surgery centre with 3 groups of 20 children. Group 1 will receive oral acetaminophen (15 mg/kg) 1 hour pre-operatively and high-dose intravenous dexamethasone (0.5 mg/kg, max. dose 10 mg) immediately after induction of anesthesia. Group 2 will receive oral acetaminophen elixir (15 mg/kg) 1 hour pre-operatively and low-dose intravenous dexamethasone (0.15 mg/kg, maximum of 8 mg) immediately after induction of anesthesia. Group 3 will receive an oral placebo 1 hour pre-operatively and low dose intravenous dexamethasone (0.15 mg/kg, maximum of 8 mg) immediately after induction of anesthesia. Dose of dexamethasone is a potential confounder if patients in the low-dose dexamethasone groups weigh enough to obtain the maximum dose (8 mg). We expect this occurrence to be rare, as dexamethasone will be dosed for ideal bodyweight, but subgroup analysis by actual dose received will be performed to compare the two dosing regimens (0.15mg/kg and 0.5 mg/kg).
In addition to these medications, patients will receive the standard peri-operative care at our centre, which consists of intra- operative ondansetron at the discretion of the anesthesiologist, and standing orders for acetaminophen (15 mg/kg) and ibuprofen (10 mg/kg) around the clock. Patients older than five years also receive morphine elixir (0.1 mg/kg rounded down to the nearest 0.5 mg) p.r.n (when necessary) at the discretion of the nurse. Thus, patients of all three groups will receive adequate post-operative symptom control. The Pediatric Otolaryngologist (Dr. Josee Paradis, Dr. Julie Strychowsky, or Dr. Murad Husein) who is the patient's physician and will be performing the tonsillectomy, will initially approach the participant and substitute decision maker (SDM) to describe the study. If the patient and SDM agree to consider the study, the study will be described in more detail and study consent/assent will be obtained by a research assistant or a physician (who is not the primary physician). We will recruit a convenience sample of 60 patients aged 3-13 years scheduled for tonsillectomy to be performed by the principal investigator or co-investigators (J.P., M.H. or J.S.). For children aged 3 to 6 years, SDM informed consent will be obtained; for children aged 7 to 12 years, SDM written consent and child assent will be requested; for children 13 years of age, written consent will be obtained from a SDM and from the child. The patients will be randomized to one of the three treatment groups by a computerized randomization table. Data from the tonsillectomy procedure, including whether analgesia was needed intraoperatively, and in the post-anesthesia care unit, will be recorded. Self-reported pain intensity will be scored on the Oucher tool, a number and picture scale validated in children age 3-13. A research assistant or nurse will be trained to obtain Oucher reports at the patient's bedside at specific post-operative events, which correspond to time points. The Oucher tool is simple to learn and takes minimal time to administer. The first pain report will be obtained once the patient wakes from anesthesia (15 - 45 min post- operation), then upon transfer to step-down care (1 - 2 hrs hour post-operation), then at 3 hours post-operation, and finally upon discharge (or at 5 hours post-operation, if the patient is not anticipated to be discharged by this time). Many of the details surrounding the operation will be gathered in post-hoc review of the patient's chart by the research assistant. If the patient is transferred from the PACU to the day surgery unit (i.e. discharge is anticipated before the end of the day), the information from the entire stay in the day surgery will be collected. If the patient is admitted to the floor (i.e. staying overnight in the hospital for observation), information will be collected from the first 4 hours after admission. The information gathered from the chart will include complications of surgery, whether or not the patient had post-operative bleeding requiring a change in management, and also whether or not the patient had post-operative bleeding that required an operating room procedure. Time to first oral fluid intake, as well as amount of oral intake (measured in quantity of popsicles) in the post-anesthesia care unit and total oral intake before discharge will also be gathered from the patient's chart, as well as the time to first administration of morphine, the dose of morphine required, and the frequency of post-operative vomiting until time of discharge. For home pain management, all patients are advised to take acetominophen (15mg/kg) every 6 hours as needed, alternating with ibuprofen (10mg/kg) every 6 hours as needed. At discharge (average 5 hours post-operation), parents/guardians will be provided with a package including the Pediatric Quality of Life Inventory with questions about oral intake and activity, as well as a space to record any incidents of vomiting, the Oucher tool to evaluate the patient's pain severity, and a medication log to keep track of the pain medication (over the counter or prescribed) that the patient has taken. Parents/guardians will be given a measured cup to record quantity of oral fluid intake for the day. Parents will be asked to fill out the first questionnaire at discharge (average 5 hours post-operation) time point, and they will be encouraged to raise any questions or concerns they have about how to complete the questionnaires. Subsequently, these instruments will be completed by parents/guardians (relationship to patient will be noted on each form and they will be encouraged to have the same parent/guardian complete the form each time) on post-operative days 1, 2, 3, 4, 5, 6, and 7 before bedtime. The research assistant will contact parents/guardians and patients by telephone on the first postoperative day to follow-up with any questions or concerns about the survey. On the last weekday before the patient's follow-up appointment, a reminder call will be made to ask the parent/guardian to bring their completed questionnaire to the appointment. On the 14th post-operative day patients will attend a follow-up visit where they will be assessed and their completed forms will be collected. If the patient had any emergency department visits related to the procedure, the research assistant will consult the hospital database to obtain information about the emergency department visit, including date, chief complaint, and management.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
- Model description
- A prospective, randomized, longitudinal, double-blinded trial at a single centre with 3 groups of 20 children each. Group 1 receives acetaminophen (15 mg/kg) 30 min-1 hr pre-operatively and high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia. Group 2 receives acetaminophen (15 mg/kg) 30 min- 1 hr pre-operatively and low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia. Group 3 receives placebo 1 hr pre-operatively and low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia. We will recruit a convenience sample of 60 patients aged 3-13 scheduled for tonsillectomy with the principal investigator or co-investigators. The patients will be placed in one of the groups by a computerized randomization table.
| Arm | Type | Receives |
|---|---|---|
| Group 1 | Experimental | Drug: Acetaminophen, Drug: High-Dose DexamethasoneAcetaminophen and High-dose dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia. |
| Group 2 | Active comparator | Drug: Acetaminophen, Drug: Low-dose DexamethasoneAcetaminophen and Low-dose Dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia |
| Group 3 | Placebo comparator | Drug: Low-dose Dexamethasone, Drug: Placebo Oral TabletPlacebo oral tablet and Low-dose Dexamethasone: an oral placebo given 1 hr pre-operatively and intravenous administration of low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia. |
Who may qualify
- Ages
- 3 to 13 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Healthy patients
- aged 3-13 years
- Level I or level II on the American Society of Anesthesiologists (ASA) physical status classification system (as determined by the anesthesiologist)
- obstructive sleep apnea or recurrent throat infections
- undergoing elective tonsillectomy with or without adenoidectomy
Key exclusion criteria (15 listed)
- Patients Level III or greater on the American Society of Anesthesiologists (ASA) physical status classification system (as determined by the anesthesiologist)
- Patients with chronic conditions that would limit our ability to develop the study according to objectives, such as neurodevelopmental conditions preventing patients from understanding the Oucher tool
- Hepatic or renal disease
- cardiac disease
- active infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AcetaminophenAlso: TylenolOral acetaminophen (15 mg/kg) 1 hr pre-operatively | Drug | Group 1, Group 2 |
| Low-dose DexamethasoneAlso: Dexamethasone sodium phosphateIntravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia | Drug | Group 2, Group 3 |
| Placebo Oral TabletAlso: PlaceboOral placebo 1 hr pre-operatively | Drug | Group 3 |
| High-Dose DexamethasoneAlso: Dexamethasone sodium phosphateIntravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia | Drug | Group 1 |
Primary outcome
Oucher pain score
Time frame: awakening from anesthesia (0.5 hours post- operation)
pain intensity on the Oucher pain tool, which includes ratings by face scale and a number scale (0-10).
8 secondary outcomes
Analgesia use
Time frame: during operation
time to first oral fluid intake
Time frame: during patient's stay in PACU (on average 5 hours)
time to first request for morphine
Time frame: during patient's stay in PACU (on average 5 hours)
dose of morphine required
Time frame: from end of operation to 7 days post-operation
vomiting
Time frame: From end of operation to 7 days post-operation
Pediatric Quality of Life Inventory
Time frame: Upon discharge (on average 5 hours post-operation), and 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days post-operation
Medication log
Time frame: discharge (on average 5 hours post-operation) to 7 days post-operation
Oucher pain score
Time frame: transfer to step-down care (1 hour post-operation), 3 hours post-operation, 5 hours post-operation, upon discharge, as well as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days post-operation
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2021.
- Individual participant dataSharing planned: No
Related trials for Tonsillitis
RecruitingPhase 4
A Single Dose of Intravenous Penicillin as an Adjunct to Oral Penicillin in the Treatment of Acute Tonsillitis, Peritonsillar Phlegmon, and Peritonsillar Abscess
Acute Tonsillitis, Peritonsillar Abscess
Recruiting
Perspectives on Antibiotics and Tracking Symptoms in Children
Urinary Tract Infection, Cellulitis
Recruiting
Suprazygomatic Maxillary Nerve Block in Pediatric Tonsillectomy
Tonsillitis
Active, not recruiting
Tonsillectomy Versus Tonsillotomy in the Treatment of Recurrent Acute Tonsillitis
Tonsillitis Recurrent
Recruiting
Transoral Ultrasound Versus no Transoral Ultrasound in Diagnostic Workup of Peritonsillar Abscess
Peritonsillar Abscess, Peritonsillar Cellulitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Josee Paradis, MD principal investigator
LHSC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Acetaminophen, Low-dose Dexamethasone and High-Dose Dexamethasone in people with Tonsillitis, run by London Health Sciences Centre at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Josee Paradis, MD (519.685.8794, Josee.Paradis@lhsc.on.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Oucher pain score (time frame: awakening from anesthesia (0.5 hours post- operation)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2021.